TIANJIN TIANYAO PHARMACEUTICALS CO., LTD.

Tianjin Tianyao Pharmaceuticals Co., Ltd.

600488

CNE000001840

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3.91 ^CNY	+0.51%		+5.39%	-20.20%

Apr. 25	Jinyao Pharma's Unit Gets Approval to Market Compound Ipratropium Bromide Solution	MT
Mar. 28	Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022

March 29, 2023 at 07:19 am EDT

Tianjin Tianyao Pharmaceuticals Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CNY 3,688.93 million compared to CNY 3,748.66 million a year ago. Revenue was CNY 3,688.93 million compared to CNY 3,748.66 million a year ago.

Net income was CNY 35.41 million compared to CNY 48.67 million a year ago. Basic earnings per share from continuing operations was CNY 0.032 compared to CNY 0.045 a year ago. Diluted earnings per share from continuing operations was CNY 0.032 compared to CNY 0.045 a year ago.

Latest news about Tianjin Tianyao Pharmaceuticals Co., Ltd.

Jinyao Pharma's Unit Gets Approval to Market Compound Ipratropium Bromide Solution	Apr. 25	MT
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Jinyao Pharma Unit's Fluconazole Chloride Passes Regulatory Evaluation	Mar. 08	MT
Jinyao Pharma Unit's Metoclopramide Hydrochloride Injection Passes Regulatory Evaluation	Feb. 29	MT
Jinyao Pharma Unit's Clindamycin Phosphate Passes Drug Regulator's Evaluation	Jan. 11	MT
Jinyao Pharmaceutical's Drugs Chosen for China's Centralized Procurement Bid	Nov. 08	MT
Jinyao Pharmaceutical Gets Nod to Market Travoprost	Nov. 03	MT
Tianyao Pharma’s Brain Injury Drug Passes Generic Drug Consistency Test	Nov. 02	MT
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Jinyao Pharmaceutical Unit's Methylcobalamin Injection Passes Drug Regulator's Evaluation	23-10-23	MT
Jinyao Pharmaceutical Gets Nod to Market Two Raw Drug Materials	23-10-12	MT
Tianjin Tianyao Pharmaceuticals Co., Ltd.(XSSC:600488) added to S&P Global BMI Index	23-09-18	CI
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Jinyao Pharmaceutical Unit's Tumor Drug Passes Regulatory Evaluation	23-08-01	MT
Jinyao Pharmaceutical Gets Nod for Marketing Application of Raw Drug Material	23-07-14	MT
Tianjin Tianyao Pharma Receives 35 Million Yuan in Government Subsidies	23-05-29	MT
Tianyao Pharma Registers Inhalation Drug	23-05-23	MT
Jinyao Pharmaceutical's Unit Gets Nod to Topical Cream's Registration	23-05-10	MT
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Tianyao Pharma Joins Bid to Have Edema Drug Added to China’s Drug Procurement Program	23-03-31	MT
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Tianjin Tianyao Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Jinyao Pharmaceutical Unit's Diazepam Injection Passes Consistency Evaluation	23-03-07	MT
Jinyao Pharmaceutical Unit Gets Regulatory Nod for Anti-Allergy Drug	22-12-27	MT
Jinyao Pharmaceutical Signs Desinging and Construction Agreement With Tianjin Pharmaceutical Design Institute	22-12-21	MT

Chart Tianjin Tianyao Pharmaceuticals Co., Ltd.

Duration

Period

Chart Tianjin Tianyao Pharmaceuticals Co., Ltd.

More charts

Company Profile

Jinyao Pharmaceutical Co Ltd, formerly Tianjin Tianyao Pharmaceuticals Co., Ltd., is a China-based company mainly engaged in the research and development, production and sales of corticosteroids and amino acid APIs and preparations. The Company's main products include dexamethasone series, prednisone series, methylprednisolone series, betamethasone series and more than 40 varieties of corticosteroid raw materials, 23 varieties of amino acid raw materials, and 16 dosage forms such as tablets, injections, ointments, creams, hard capsules, pills, freeze-dried powder injections, and inhalation preparations. The Company mainly operates in the domestic market and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-04-26 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TIANJIN TIANYAO PHARMACEUTICALS CO., LTD.	-20.20%	590M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B